Alex Kendall, CEO of Wayve, discusses the architectural shift from AV 1.0's hand-engineered robotics to AV 2.0's end-to-end deep learning. He explains how Wayve's generalization-first approach, powered by world models and diverse data, allows them to scale across hundreds of cities and multiple automotive OEMs, creating a path toward a general-purpose embodied AI foundation model.
Emmett Shear, founder of Twitch and former OpenAI interim CEO, presents a new paradigm for AI alignment called "organic alignment." He argues that the prevalent "steering and control" model is fundamentally flawed, potentially leading to disaster. Shear advocates for developing AI systems that learn to genuinely care about humans, treating alignment as a continuous process rather than a fixed state.
Dr. Fei-Fei Li discusses the history of AI, from the creation of ImageNet that sparked the deep learning revolution to the future of AI with spatial intelligence and world models. She introduces 'Marble', the first large world model, and explains its potential to unlock new frontiers in robotics, virtual production, and scientific discovery, all while emphasizing a human-centered approach to technological advancement.
Ben Lorica and Evangelos Simoudis analyze the nuances of AI-driven layoffs, categorizing them into upskilling gaps, automation, and strategic R&D shifts. They also explore the immense pressure for ROI on AI infrastructure investments, leading to the emergence of LLMOps as a form of financial management and the critical need for breaking down organizational silos.
Founders Hassaan Raza and Quinn Favret detail Tavus's evolution from a personalized video tool to an AI research lab building real-time, agentic AI humans. They explore the foundational models for perception and rendering, the launch of Tavus PALs, and their vision for AI humans as the next major computing interface.
Venture capitalists Elliot Hershberg and Lada Nuzhna analyze the structural crises facing the biotech industry, from Eroom's Law driving drug development costs to $2.5 billion, to China's rapid, low-cost clinical trials outmaneuvering US startups. They argue that for American biotech to survive, it must shift from competing on commoditized platforms to inventing entirely new modalities and medicines that are impossible to create without bleeding-edge tools like AI, targeting massive opportunities like aging.